Clinical Trial Update: Study of the Electrocardiographic Effects of TA-8995 [Phase 1]

View source ↗

Summary

A completed Phase 1 study evaluating the electrocardiographic effects of TA-8995 in dyslipidaemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidaemia

Drugs mentioned

• TA-8995

Snippet

Sponsor: Xention Ltd | Conditions: Dyslipidaemia | Phase 1 | Status: COMPLETED